AVGR news

Search

Article Tools

Set News Alert

Companies Mentioned

Symbol	Last	Change
AVGR	$1.74	+1.75%

Back to News Overview

Avinger, Inc.'s CEO Jeff Soinski on Q2 2022 Results -- Earnings Call Transcript >AVGR

8/12/22 6:57 PM ET (Dow Jones)Print

From Seeking Alpha: Avinger, Inc.'s CEO Jeff Soinski on Q2 2022 Results -- Earnings Call Transcript https://seekingalpha.com/article/4533788-avinger-inc-s-avgr-ceo-jeff-soinski-on-q2-2022-results-earnings-call-transcript?utm_source=dowjonesnewswire.com&utm_medium=referral

(END) Dow Jones Newswires

August 12, 2022 18:57 ET (22:57 GMT)

Analyst Reports

Search News

JSPR

 

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA. The listed name for JSPR is Jasper Therapeutics, Inc. Common Stock.

research daily price

ID	stock	DATE	BROKER	Avg	SHARE	market	percent	net loss or gain	open	high	Low	Float	avg volume	52High	52 Low	Remark	COMPANY
15	JSPR	8/11/2022	RH	$2.22	4.00	$2.22	0.07%	$0.01	$2.13	$2.17	$2.11	3156	40799	$18.88	$1.73	one week + 5.21 % one months -5.92 % 3months 24.49 % one year 77.64 %	stem cell genetic manipulation

GCI

 

Gannett
GCI
1
$2.35
$2.34
$0.01
2.32